These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Phase III trial of IL-2. AIDS Patient Care STDS; 1999 Dec; 13(12):753-4. PubMed ID: 10743542 [No Abstract] [Full Text] [Related]
3. AIDS trials take on peer review. Cohen J Science; 1996 Jan; 271(5245):20-1. PubMed ID: 8539588 [No Abstract] [Full Text] [Related]
4. Alternative approach to AIDS defense shows promise. Marino D Dent Today; 1997 Jan; 16(1):28, 31. PubMed ID: 9560623 [No Abstract] [Full Text] [Related]
5. Talking about anti-viral drug regimens: 38th annual ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy. Laurence J AIDS Patient Care STDS; 1998 Nov; 12(11):817-8. PubMed ID: 11362036 [No Abstract] [Full Text] [Related]
6. Hopes for HIV eradication dim as stopping HAART allows resurgence. Stephenson J JAMA; 1999 Oct; 282(14):1317-8. PubMed ID: 10527163 [No Abstract] [Full Text] [Related]
7. Adding IL-2 to anti-HIV drugs increases CD4+ cell counts without raising HIV levels. AIDS Read; 2000 Sep; 10(9):522-3. PubMed ID: 11019440 [No Abstract] [Full Text] [Related]
8. Aldesleukin shows promise. AIDS Patient Care STDS; 1999 May; 13(5):307. PubMed ID: 10356813 [No Abstract] [Full Text] [Related]
9. Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: results of Pediatric AIDS Clinical Trials Study 402. Pahwa S; Muresan P; Sleasman J; Fenton T; Moye J; Deveikis A; Wara D; Van Dyke R; J Allergy Clin Immunol; 2007 Jun; 119(6):1538-41. PubMed ID: 17418382 [No Abstract] [Full Text] [Related]
10. Interleukin-2 in HIV infection. Minor JR Am J Health Syst Pharm; 1995 Jun; 52(12):1345-6. PubMed ID: 7656123 [No Abstract] [Full Text] [Related]
11. 'Better adherence vital in AIDS therapies'. Macilwain C Nature; 1997 Nov; 390(6658):326. PubMed ID: 9389462 [No Abstract] [Full Text] [Related]
12. Generic drugs allowed in global trial of AIDS therapy. Check E Nature; 2004 Oct; 431(7012):1028. PubMed ID: 15510113 [No Abstract] [Full Text] [Related]
13. IL-2 immunotherapy does not benefit patients taking antiretrovirals. AIDS Patient Care STDS; 2009 Mar; 23(3):221-2. PubMed ID: 19866543 [No Abstract] [Full Text] [Related]
14. Improvement in CD4+ cell counts despite persistently detectable HIV load. Levitz SM N Engl J Med; 1998 Apr; 338(15):1074-5. PubMed ID: 9537882 [No Abstract] [Full Text] [Related]
15. US to limit AIDS trials in developing nations. Ready T Nat Med; 2003 Jun; 9(6):629. PubMed ID: 12778141 [No Abstract] [Full Text] [Related]
16. AmFAR extols FDA on rapid approval of two protease inhibitors. AIDS Patient Care STDS; 1996 Jun; 10(3):193-4. PubMed ID: 11361645 [No Abstract] [Full Text] [Related]
17. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses. Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078 [TBL] [Abstract][Full Text] [Related]
19. Science and the control of AIDS. Varmus H; Nathanson N Science; 1998 Jun; 280(5371):1815. PubMed ID: 9669926 [No Abstract] [Full Text] [Related]
20. Global AIDS trial denied patients as US balks at generic drug use. Check E Nature; 2004 Sep; 431(7008):493. PubMed ID: 15457219 [No Abstract] [Full Text] [Related] [Next] [New Search]